CHINA PHARMA HOLDINGS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
CHINA PHARMA HOLDINGS, INC. (CPHI) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $82.00 per share for the 1-month period ending 2023-06-30, per its 10-Q filed 2023-08-14.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2023-08-14
- CHINA PHARMA HOLDINGS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2023-03-31 was $85.00.
- CHINA PHARMA HOLDINGS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $85.00, a 19288.82% increase from fiscal 2021.
- CHINA PHARMA HOLDINGS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2021 was $0.44.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price as first filed | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 0 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 1 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 1 month as first filed | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|---|---|---|
| 2023-06-30 | $82.00 10-Q · filed 2023-08-14 | ||||||
| 2023-06-23 | $0.28 10-Q · filed 2023-08-14 | ||||||
| 2023-06-06 | $0.27 10-Q · filed 2023-08-14 | ||||||
| 2023-05-24 | $0.25 10-Q · filed 2023-08-14 | ||||||
| 2023-05-01 | $0.26 10-Q · filed 2023-08-14 | ||||||
| 2023-04-07 | $0.28 10-Q · filed 2023-08-14 | ||||||
| 2023-03-31 | $85.00 10-Q · filed 2023-05-12 | ||||||
| 2023-03-02 | $0.57 10-Q · filed 2023-08-14 | ||||||
| 2023-01-18 | $0.76 10-Q · filed 2023-08-14 | ||||||
| 2023-01-05 | $0.76 10-Q · filed 2023-08-14 | ||||||
| 2022-12-31 | $85.00 10-K · filed 2023-03-30 | ||||||
| 2022-12-14 | $0.83 10-K · filed 2023-03-30 | ||||||
| 2022-12-13 | $0.91 10-K · filed 2023-03-30 | ||||||
| 2022-12-05 | $0.83 10-K · filed 2023-03-30 | ||||||
| 2022-12-01 | $0.83 10-K · filed 2023-03-30 | ||||||
| 2022-10-17 | $1.12 10-K · filed 2023-03-30 | ||||||
| 2022-08-03 | $1.75 10-K · filed 2023-03-30 | $0.18 10-Q · filed 2022-11-14 | |||||
| 2022-06-13 | $0.20 10-Q · filed 2022-11-14 | ||||||
| 2022-06-09 | $0.76 10-Q · filed 2023-05-12 | $0.20 10-Q · filed 2022-08-11 | $0.20 10-Q · filed 2022-11-14 | ||||
| 2022-03-30 | $3.13 10-K · filed 2023-03-30 | $0.31 10-Q · filed 2022-08-11 | $0.31 10-Q · filed 2022-11-14 | ||||
| 2022-03-21 | $3.11 10-K · filed 2023-03-30 | $0.31 10-Q · filed 2022-08-11 | $0.31 10-Q · filed 2022-11-14 | ||||
| 2021-12-31 | $0.44 10-K · filed 2022-03-30 | ||||||
| 2021-11-19 | $0.60 10-Q · filed 2022-11-14 | $5.96 10-Q · filed 2023-08-14 | $0.60 10-K · filed 2022-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |